Our data may facilitate the development of clinical trials to test the efficacy of MM-121 in combination with trastuzumab or paclitaxel in HER2-overexpressing breast cancer patients who have developed resistance to trastuzumab or paclitaxel. The gene discussed is ERBB2; the disease is breast carcinoma.